Why Grail Stock Has Plunged 50% Despite Earnings Beat

Core Viewpoint - Grail's stock experienced a significant decline of 50% following the release of disappointing results from a trial assessing its cancer detection tool, despite the company beating earnings expectations [1]. Company Summary - Grail is a biotechnology company known for its Galleri blood test, which aims to screen for multiple cancers before symptoms appear [1]. - The stock is on track for its largest single-day percentage drop in history, indicating a severe market reaction to the trial results [1]. Industry Context - The biotechnology sector is highly sensitive to clinical trial outcomes, and disappointing results can lead to drastic stock price fluctuations [1].